Clinical Trial Update: A Long-term Efficacy and Safety of NTQ5082 Capsules [Phase 3]

View source ↗

Summary

This update describes a Phase 3 long-term efficacy and safety study of NTQ5082 capsules for paroxysmal nocturnal hemoglobinuria, currently not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Paroxysmal Nocturnal Hemoglobinuria

Drugs mentioned

• NTQ5082 capsules (NTQ5082)

Snippet

Sponsor: Nanjing Chia-tai Tianqing Pharmaceutical | Conditions: Paroxysmal Nocturnal Hemoglobinuria | Phase 3 | Status: NOT_YET_RECRUITING